Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.40 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.40 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.40 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476023 | 0.91 | KIF11 (0.43) | KIF11MAPK1MEN1KMT2AATM | |
| SCHEMBL3265797 | 0.90 | LTA4H (0.50) | KIF11MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL30610089 | 0.82 | KIF11 (0.49) | KIF11MAPK1MEN1KMT2ANPC1 | |
| SCHEMBL14356107 | 0.82 | KIF11 (0.49) | KIF11MAPK1MEN1KMT2ANPC1 | |
| SCHEMBL10276699 | 0.81 | KIF11 (0.46) | KIF11MAPK1NPC1RAB9ALMNA | |
| SCHEMBL4363002 | 0.80 | KIF11 (0.49) | KIF11MAPK1MEN1KMT2ALMNA | |
| SCHEMBL12225852 | 0.80 | KIF11 (0.49) | KIF11MAPK1MEN1KMT2ALMNA | |
| SCHEMBL6854126 | 0.80 | KIF11 (0.42) | KIF11MEN1KMT2AATMNPC1 | |
| SCHEMBL6750468 | 0.80 | KIF11 (0.42) | KIF11MEN1KMT2AATMNPC1 | |
| SCHEMBL6750471 | 0.78 | KIF11 (0.47) | KIF11MAPK1NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1232157-B1 | NON-AGGREGATING, NON-QUENCHING OLIGOMERS COMPRISING NUCLEOTIDE ANALOGUES; METHODS OF SYNTHESIS AND USE THEREOF | EPOCH BIOSCIENCES INC (US) | 2010-05-05 | — | — | EP | disclosed |
| US-6972328-B2 | Non-aggregating non-quenching oligomer comprising nucelotide analogs, method of synthesis and use thereof | EPOCH BIOSCIENCES, INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20050239121-A1 | Non-aggregating non-quenching oligomers comprising nucleotide analogs; methods of synthesis and use thereof | EPOCH BIOSCIENCES, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| US-20040116689-A1 | Non-aggregating non-quenching oligomer comprising nucelotide analogs, method of synthesis and use thereof | EPOCH BIOSCIENCES, INC. (US) | 2004-06-17 | — | — | US | disclosed |
| US-6660845-B1 | Peptide nucleic acids in which one or more purine bases are substituted by a pyrazolo(5,4-d)pyrimidine or by a 7-deazapurine purine analogue; improved hybridization analysis | EPOCH BIOSCIENCES, INC. | 2003-12-09 | — | — | US | disclosed |
| US-6465650-B1 | INTERMEDIATE STEPS IN PREPARING PEPTIDE NUCLEIC ACIDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-15 | — | — | US | disclosed |
| EP-1232157-A2 | NON-AGGREGATING, NON-QUENCHING OLIGOMERS COMPRISING NUCLEOTIDE ANALOGUES; METHODS OF SYNTHESIS AND USE THEREOF | Epoch Biosciences, Inc. (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001038584-A2 | NON-AGGREGATING, NON-QUENCHING OLIGOMERS COMPRISING NUCLEOTIDE ANALOGUES; METHODS OF SYNTHESIS AND USE THEREOF | EPOCH BIOSCIENCES, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| US-6075143-A | USEFUL FOR FORMING PEPTIDE NUCLEIC ACIDS OR HYBRID OF PEPTIDE NUCLEIC ACIDS AND DEOXYNUCLEIC ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-06-13 | — | — | US | disclosed |
| EP-0672661-A1 | Substituted N-ethyl-glycinderivatives for the preparation of PNA and PNA-/DNA hybrides | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239121-A1 | Non-aggregating non-quenching oligomers comprising nucleotide analogs; methods of synthesis and use thereof | RNGTT, PABPC4, ADAR | KIF11 3673/4885CYP1A2 4059/4885CYP2C19 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.